XML 45 R35.htm IDEA: XBRL DOCUMENT v3.21.2
Additions and Returns of Product Rights - Narrative (Details) - USD ($)
1 Months Ended 3 Months Ended 6 Months Ended 24 Months Ended
Nov. 30, 2018
Nov. 30, 2016
Mar. 31, 2021
Jun. 30, 2021
Sep. 30, 2021
Dec. 31, 2020
Jul. 31, 2020
Business Acquisition [Line Items]              
Financial consideration received in exchange for product license rights, installment payments     $ 3,000,000.0        
Clinigen              
Business Acquisition [Line Items]              
Discontinued operations income       $ 1,000,000.0      
Clinigen | Scenario, Forecast              
Business Acquisition [Line Items]              
Financial consideration received in exchange for product license rights         $ 5,000,000    
Vaprisol              
Business Acquisition [Line Items]              
Payment to acquire business upon closing $ 20,000,000.0            
Other Payments to Acquire Businesses $ 5,000,000.0            
Percentage of tiered royalty payments (up to) 20.00%            
Additional liability       7,357,081   $ 8,200,552  
Vaprisol | Other current liabilities              
Business Acquisition [Line Items]              
Additional liability       2,900,000      
Vaprisol | Other long-term liabilities              
Business Acquisition [Line Items]              
Additional liability       4,500,000      
Methotrexate              
Business Acquisition [Line Items]              
Payment to acquire business upon closing   $ 100,000          
Additional liability           $ 1,000,000.0 $ 1,000,000.0
Liability recorded   $ 900,000          
Vested common stock, value       900,000      
Net intangible assets       $ 2,700,000      
Methotrexate | Restricted Stock              
Business Acquisition [Line Items]              
Unvested restricted shares (in shares)   180,000